Dacemazine

Dacemazine (INN, also known as Ahistan and Histantine)[1] is a phenothiazine derivative which acts as a histamine antagonist at the H1 subtype. First described in 1951, it was never marketed as a drug on its own, although a combination of dacemazine and di-tert-butylnaphthalenesulfonate was sold as an antispasmodic and antitussive under the trade name Codopectyl.[1] It was also assessed as a possible anticancer drug.[2]

Dacemazine
Clinical data
ATC code
  • none
Identifiers
  • 2-dimethylamino-1-phenothiazin-10-ylethanone
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H16N2OS
Molar mass284.38 g·mol−1
3D model (JSmol)
  • O=C(N1c3c(Sc2c1cccc2)cccc3)CN(C)C
  • InChI=1S/C16H16N2OS/c1-17(2)11-16(19)18-12-7-3-5-9-14(12)20-15-10-6-4-8-13(15)18/h3-10H,11H2,1-2H3 Y
  • Key:HKUCYAHWPVLPFN-UHFFFAOYSA-N Y
 NY (what is this?)  (verify)

References
  1. Triggle DJ, Ganellin CR, MacDonald F (1996). Dictionary of Pharmacological Agents. Vol. 1. Boca Raton: Chapman & Hall/CRC. p. 711. ISBN 0-412-46630-9. Retrieved on August 2, 2008 through Google Book Search.
  2. Karolyhazy G, Havas I, Jansco G, Kapas L, Sellei C (August 1952). "[The anticarcinogenic effect of dimethylaminoacetyl-phentiazide (ahistan)]". Kiserletes Orvostudomany (in Romanian). 4 (4): 260–2. PMID 13023855.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.